Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Oral QPX7831 in Healthy Adults
NCT04578873Phase 1Completed
- Sponsor
- Qpex Biopharma
- Start
- Apr 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of xeruborbactam isoboxil in gram-negative bacterial infections (2 arms), sponsored by Qpex Biopharma. Primary endpoints: Incidence of Treatment-Emergent Adverse Events up to 17 days, Changes from baseline in safety parameters up to 17 days and 5 more. Started Apr 2021; status: completed.
02
Drugs
xeruborbactam isoboxil
03
Conditions
gram-negative bacterial infections
Beyond the preview
Go deeper on NCT04578873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04578873.